Abstract: A long-range electrochromic fiber for infrared camouflage and preparation method thereof are disclosed. The method includes: coating indium tin oxide dispersion, electrolyte solution, and electrochromic material on the surface of the metal fiber sequentially, and preparing counter electrodes and polymer protective layer on the outside of the electrochromic layer to obtain the long-range electrochromic fiber. The obtained long-range electrochromic fiber can realize the regulation of infrared emissivity, can be continuously prepared for more than 100 meters and has a good application prospect in infrared camouflage, wearable display, etc.

Abstract: The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to oral and gastric mucositis. Also provided are codon-optimized nucleic acids encoding for Smad7 fusion proteins.

Abstract: The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to oral and gastric mucositis. Also provided are codon-optimized nucleic acids encoding for Smad7 fusion proteins.

Abstract: The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to oral and gastric mucositis. Also provided are codon-optimized nucleic acids encoding for Smad7 fusion proteins.

Abstract: The invention provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systematically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to mucositis.

Abstract: The invention provides a peptide construct comprising a cell penetrating peptide and an inhibitory peptide that interferes with the interaction between E1A and CtBP. The invention also provides related pharmaceutical composition comprising such a peptide construct. Also provided is a conjugate comprising such a peptide construct and a carrier molecule. The invention also provides related pharmaceutical compositions. Also provided are related methods of inhibiting cell proliferation in an individual and methods of treating cancer in by such pharmaceutical compositions. The present application also provides methods of treating an inflammatory disease and inhibiting inflammation in an individual comprising administering to the individual an effective amount of a therapeutic agent comprising an inhibitory peptide that interferes with the interaction between E1A and CtBP.

Abstract: The invention provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systematically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to mucositis.

Abstract: The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to oral and gastric mucositis. Also provided are codon-optimized nucleic acids encoding for Smad7 fusion proteins.

Abstract: The invention provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systematically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to mucositis.

Abstract: The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to oral and gastric mucositis. Also provided are codon-optimized nucleic acids encoding for Smad7 fusion proteins.

Abstract: The invention provides a peptide construct comprising a cell penetrating peptide and an inhibitory peptide that interferes with the interaction between E1A and CtBP. The invention also provides related pharmaceutical composition comprising such a peptide construct. Also provided is a conjugate comprising such a peptide construct and a carrier molecule. The invention also provides related pharmaceutical compositions. Also provided are related methods of inhibiting cell proliferation in an individual and methods of treating cancer in by such pharmaceutical compositions. The present application also provides methods of treating an inflammatory disease and inhibiting inflammation in an individual comprising administering to the individual an effective amount of a therapeutic agent comprising an inhibitory peptide that interferes with the interaction between E1A and CtBP.

Abstract: The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to oral and gastric mucositis. Also provided are codon-optimized nucleic acids encoding for Smad7 fusion proteins.

Abstract: The invention relates to a catalyst for selective synthesis of high-quality gasoline fractions from syngas and the preparation method of the catalyst. This catalyst consists of cobalt, a promoter and molecular sieve, wherein cobalt is presented in an amount of 1-30%, the promoter is represented in an amount of 0.01-5% and the balance is molecular sieve based on the weight of the catalyst. This catalyst provides superior selectivity for C5-C11 isoparaffins and relatively lower selectivity for wax-type hydrocarbons with more than 20 carbon atoms. Thereof, this catalyst can be used for the synthesis of high-quality gasoline and is good at preventing catalyst coking. Besides, the invention provides a preparation method of the catalyst.

Abstract: The invention provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systematically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to mucositis.

Abstract: The invention provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to mucositis.

Abstract: Provided is a method for performing layer Q factor inversion by using an amplitude spectrum attribute of a down going wave of vertical seismic profile data in a geophysical exploration data processing technology. In the method, first an F-K (frequency-wave number) method is used to perform wave field separation on VSP original data, so as to obtain a down going wave; a down going wavelet and a monitoring wavelet are selected to undergone Fourier transform to obtain an amplitude spectrum, polynomial fitting is performed on the amplitude spectrum to obtain an equivalent Q, and a formula between the equivalent Q and a layer Q is used to perform inversion, so as to obtain the layer Q. The method has a strong capability of resisting random disturbance, and is capable of removing a difference of triggering wavelet. The algorithm is simple and can greatly save workload; moreover, the layer Q value obtained through inversion has a desirable stability and high precision.

Abstract: A method for link adaptation includes: classifying a radio channel; setting a set of link adaptation modes; and selecting a corresponding link adaptation mode according to a radio channel type. An apparatus for link adaptation includes: a classification module for performing a classification on a radio channel; a setting module for setting a set of link adaptation modes; and a mode selection module for selecting a corresponding link adaptation mode from the setting module according to a radio channel type of the classification. The present invention accordingly selects effective link adaptation modes in accordance with different types of radio channels, and is able to ensure to implement the maximum system throughput in different fading channels and maintain the stable and reliable link quality.

Abstract: The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to oral and gastric mucositis. Also provided are codon-optimized nucleic acids encoding for Smad7 fusion proteins.

Abstract: The invention relates to a catalyst for selective synthesis of high-quality gasoline fractions from syngas and the preparation method of the catalyst. This catalyst consists of cobalt, a promoter and molecular sieve, wherein cobalt is presented in an amount of 1-30%, the promoter is represented in an amount of 0.01-5% and the balance is molecular sieve based on the weight of the catalyst. This catalyst provides superior selectivity for C5-C11 isoparaffins and relatively lower selectivity for wax-type hydrocarbons with more than 20 carbon atoms. Thereof, this catalyst can be used for the synthesis of high-quality gasoline and is good at preventing catalyst coking. Besides, the invention provides a preparation method of the catalyst.

Abstract: The invention provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to mucositis.